Johnson & Johnson (JNJ)

NYQ – Real vaqt narxi. Valyuta: USD

224.26

+2.83 (1.28%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter.

11.05.2026

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9th, 2026. Management will participate in a Fireside Chat at 10:00 a.m. Eastern Time. This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. The audio webcast replay will be available approximately 48 hours after the webcast.

11.05.2026

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

Oral presentations feature CAPLYTA ® long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms 18 abstracts highlight J&J's leadership and deep portfolio in neuropsychiatry at the American Psychiatric Association (APA) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings TITUSVILLE, N.J., May 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 18 abstracts featuring new and encore data from the Company's robust neuropsychiatry portfolio and pipeline will be presented at two upcoming scientific meetings: the American Psychiatric Association (APA) Annual Meeting (May 16-20, San Francisco) and the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (May 26-29, Miami).

10.05.2026

2 Dividend Stocks That Are No-Brainer Buys in May

The geopolitical conflict in the Middle East has pushed oil prices higher and increased concerns about a recession. The S&P 500 index continues to hold near its all-time highs.

08.05.2026

3 Unstoppable Dividend King Stocks to Buy Right Now for Less Than $550

Johnson & Johnson has increased its dividend for 64 consecutive years. Procter & Gamble recently extended its dividend growth streak to 70 straight years.

08.05.2026

Warren Buffett and Berkshire Hathaway Own 2 Dividend Kings That Will Never Be Sold

Warren Buffett stepped down as CEO of Berkshire Hathaway (BRK-B | BRK.B Price Prediction) on December 31, 2025, after six decades leading the conglomerate he transformed from a struggling textile mill into a $1 trillion empire.

07.05.2026

Darzalex, Erleada & New Drugs Keep J&J's Oncology Engine Charged in Q1

Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.

Videolar

02.05.2026

Positive

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

28.04.2026

Positive

Why These 3 Forever Stocks Belong on Your Watchlist

14.04.2026

Positive

Johnson & Johnson CFO on the company's robotic surgical system

14.04.2026

Positive

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
JNJ	Daiwa Securities	Outperform	undefined >> $203	October 20th 2025
JNJ	Wells Fargo	Overweight	undefined >> $212	October 3rd 2025
JNJ	Guggenheim	Buy	undefined >> $206	September 23rd 2025
JNJ	Erste Group	Buy	undefined >> undefined	July 23rd 2025
JNJ	Leerink Partners	Market Perform	undefined >> $153	May 13th 2025

Press-relizlar

12.05.2026

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter.

11.05.2026

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

07.05.2026

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

Generation Fine launches after global survey finds nearly 4 in 5 patients living with major depressive disorder don't believe antidepressants will help them reach remission Campaign draws on expertise of Mental Health America and elevates the voices of leading mental health advocates, including Kyle Long, television studio analyst, retired National Football League (NFL) player NEW BRUNSWICK, N.J., May 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the launch of Generation Fine, a global campaign designed to challenge what it means to feel "fine" in depression care and empower patients to take the first step in moving beyond "good enough" by talking with their healthcare provider.

05.05.2026

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

TREMFYA ® demonstrated significantly higher rates of combined fistula remission – complete external closure of draining fistulas and absence of fluid collection on MRI – compared to placebo at Week 24 First study of its kind in 20 years for this debilitating manifestation of Crohn's disease presented as late-breaking data at Digestive Disease Week 2026 CHICAGO, May 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from the Phase 3 FUZION study evaluating TREMFYA® (guselkumab) in adults with active perianal fistulizing Crohn's disease (CD). At Week 24, TREMFYA demonstrated significantly higher rates of combined fistula remission, a highly stringent endpoint defined as complete external closure of draining fistulas and absence of fluid collection on MRI, compared to placebo.1 Remission in patients with this complicated manifestation remains difficult to achieve, and this is the first randomized control trial of an approved therapy in inflammatory bowel disease (IBD) that demonstrates efficacy in adults with active perianal fistulizing Crohn's disease in 20 years.

Johnson & Johnson (JNJ)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Johnson & Johnson (JNJ)

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

2 Dividend Stocks That Are No-Brainer Buys in May

3 Unstoppable Dividend King Stocks to Buy Right Now for Less Than $550

Warren Buffett and Berkshire Hathaway Own 2 Dividend Kings That Will Never Be Sold